An interventional study of modified vaginal tampon in Cancer, sponsored by Irene Burger. Completed at 1 site in Switzerland. Open to female participants aged 20 Years to 48 Years. Per ClinicalTrials.gov, last updated 2019-08-28.
Sponsored by Irene Burger · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The etiology of FDG uptake in vaginal tampons during PET/CT examinations remains unclear and can potentially impair image interpretation.
The aim of this study is to determine the etiology of this artefact and identify potential means how to prevent it.
In this prospective, Institutional Review board approved study we included 44 women referred to FDG PET/CT for staging or follow-up in an oncology setting. All women were provided a normal commercial or modified vaginal tampon with a silicon coated base to be used during examination. Images were analyzed to determine the localization and the FDG uptake in the tampons. Between the uptake phase and imaging, all patients were asked to void. After image acquisition, tampons were individually analyzed for creatinine concentration, blood traces, position relative to the pubococcygeal line, and FDG activity. Statistical significance was determined by means of the Mann-Whitney U test.
10,837 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 44 is below the median of 60 across 7,716 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Irene Burger is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion criteria: premenopausal women with known or suspected who regularly used vaginal tampons during menstruation and thus were familiar with their use
Exclusion criteria: No cervical or genital carcinoma. No vaginal infection.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients using modified vaginal tampons during FDG PET/CT
Device: modified vaginal tampon
Patients using unmodified vaginal tampons during FDG PET/CT
Device: modified vaginal tampon
modified vaginal tampons versus unmodified vaginal tampons, comparing the urinary contamination
Also known as: Ob® Regular; Johnson & Johnson, with silicon seal
Number of FDG Positive Tampoons
Number of FDG positive Tampoons with an SUV \> 3
Time frame: 1 month
Tampon Position Relative to the Pubococcygeal Line
measure tampon position in regard to the pubococcygeal line to identify if positioning is responsible for urinary contamination.
Time frame: 1 month
Premenopausal women referred for FDG PET/CT examination for staging or follow up of malign disease, were given a modified or unmodified vaginal tampon during the PET/CT examination.
| Milestone | Modified Vaginal Tampons | Unmodified Vaginal Tampons |
|---|---|---|
| Started | 20 | 24 |
| Completed | 20 | 24 |
| Not completed | 0 | 0 |
Number of FDG positive Tampoons with an SUV \> 3
| FDG positive tampons | Modified Vaginal Tampons | Unmodified Vaginal Tampons |
|---|---|---|
| Number of FDG Positive Tampoons | 2 | 10 |
measure tampon position in regard to the pubococcygeal line to identify if positioning is responsible for urinary contamination.
| mm | Modified Vaginal Tampons | Unmodified Vaginal Tampons |
|---|---|---|
| Tampon Position Relative to the Pubococcygeal Line | 5.9 ± 17 | 5.1 ± 11 |
Collected over During FDG PET/CT scan (2 hours). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Modified Vaginal Tampons | — | 0/20 (0%) | 0/20 (0%) |
| Unmodified Vaginal Tampons | — | 0/24 (0%) | 0/24 (0%) |
| Age, Categorical(Participants) | Modified Vaginal Tampons | Unmodified Vaginal Tampons | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 20 | 24 | 44 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Modified Vaginal Tampons | Unmodified Vaginal Tampons | Total |
|---|---|---|---|
| Mean | 39 ± 7.7 | 37 ± 8.4 | 39 ± 8.5 |
| Sex: Female, Male(Participants) | Modified Vaginal Tampons | Unmodified Vaginal Tampons | Total |
|---|---|---|---|
| Female | 20 | 24 | 44 |
| Male | 0 | 0 | 0 |
| Region of Enrollment(participants) | Modified Vaginal Tampons | Unmodified Vaginal Tampons | Total |
|---|---|---|---|
| Switzerland | 20 | 24 | 44 |
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2010 to primary completion in Aug 2010, 6 months.
Results were first posted in Aug 2019, 9 years after primary completion.
Of 1,993 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's 6 months is below that.
Counting every sponsor, half of 2,068 studies reached it within 29 months; a quarter within 13 and three quarters within 52.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Irene Burger